Assessment of the INVOcell Intravaginal Culture System

Infertility Clinical Trial

Official title:

Assessment of the INVOcell Intravaginal Culture System During 5-day (120 Hours) Vaginal Incubation

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT04246268
• Other study ID #: CP-017
• Status: Suspended
• Phase: N/A
• Start date: October 2020
• Est. completion date: March 2022

Study information

• Verified date: July 2020
• Source: INVO Bioscience, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The INVOcell intravaginal culture system is a prescription device intended for preparing, holding, and transferring human gametes or embryos during intravaginal in vitro fertilization or intravaginal culture procedures.

The original (FG-002) INVOcell culture system was FDA cleared through De Novo application (DEN150008). The purpose of this study is to evaluate the INVO Bioscience modified INVOcell system, comprised of the INVOcell Intravaginal Culture Device and Retention Device, in terms of the following:

2.1 Effectiveness of achieving fertilization, implantation, embryo development, clinical pregnancy, and live birth after 5-days of continuous vaginal incubation.

2.2 The comfort and retention of the INVOcell device and retention system intravaginally.

Description:

This is a Pivotal, single arm, multicenter, open label trial to evaluate the efficacy, comfort and retention of the INVOcell Intravaginal Culture Device and Retention Device over 5-days vaginal incubation. The effectiveness of the INVOcell device will be tested on a select population of infertile couples at several in vitro fertilization (IVF) centers. The providers at each center will conduct the processes of ovarian stimulation, egg retrieval and embryo transfer per the standard protocols for their centers. The planned sample size is 180 participants across 3 sites (60 participants per site).

The objective of this study is to assess the efficacy, comfort and retention of the INVOcell with the retention device, and demonstrate superiority following 5-day vaginal incubation as compared to current 3-day vaginal incubation indication.

Specifically, the following will be assessed:

1. The INVO Procedure using the INVOcell Intravaginal Culture Device can effectively maintain 5-days of continuous vaginal incubation with the transfer of blastocyst(s) at the end of the 5-days.

2. The Retention Device retains the INVOcell in the vaginal cavity and is well tolerated during the 5-days of continuous vaginal incubation.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 180
• Est. completion date: March 2022
• Est. primary completion date: July 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 37 Years

Eligibility

Inclusion Criteria:

Women diagnosed with:

• Tubal factor

• Endometriosis (stage I or II)

• Ovulatory dysfunction

• Multiple female factors

• Males with mild male factor [mild male factor is defined as meaning: two or more semen analyses that have one or more variables which fall below the 5th centile as defined by the World Health Organization (WHO, 2010)]

Couples with:

• Unexplained Infertility

• Multiple factors, of female and/or male origin

The pre-selected couples will be included in the study only if they fulfill the more specific inclusion and exclusion criteria below:

• Couples may be included in the study only if they have been informed about the study and have given their written consent.

• Infertile couples with failure to conceive a diagnosed pregnancy after one year of unprotected intercourse (6 months if the woman's age is 35 years or more). This one-year requirement need not be fulfilled if oligomenorrhea or tubal factor is present, or donor sperm use is planned

• IVF has been determined by the physician to be their next appropriate treatment

• Women with desire for pregnancy using donor sperm will be eligible even absent infertility factors.

Women included in the study should:

• Be between the age of 18 and 37 years (has not reached her 38th birthday at the time of enrollment).

• Have an anti-Müllerian hormone (AMH) level = 0.8 ng/mL

• Have a normal uterine cavity as assessed in the past year by HSG, SHG or hysteroscopy. Prior tubal ligation is acceptable.

• Partner semen analysis within the past year must show a total of = 15 million motile spermatozoa.

Exclusion Criteria:

• Inability to read and speak English fluently

• One (1) or more recurrent vaginitis or bacterial vaginosis (BV) requiring medical attention.

• A history of toxic shock syndrome

• Known allergies to plastic or silicone

• Had pelvic surgery within the past 8 weeks, excluding laparoscopy with or without salpingectomy (ies) or hysteroscopy with or without polypectomy

• Had pelvic inflammatory disease (PID) within the past 3 months and were treated with antibiotics

• Severe endometriosis (stage III-IV) or endometrioma(s) (past or present)

• Clinical signs of current vaginal infection

• Significant abnormalities of the vaginal cavity

• Submucous or intramural fibroids (>2 cm diameter)

• Hydrosalpinx

• Uncontrolled chronic illness, e.g. autoimmune disease, diabetes. Appropriately treated hypothyroidism, hypertension, dyslipidemia, e.g., are not exclusions.

• BMI >36.0 kg/m2

• Donor oocytes

• Antral follicle count (AFC; at cycle baseline) < 6

• Previously assessed as having a poor response to ovarian stimulation

• Patients with polycystic ovary syndrome (PCOS) meeting NIH (1990) criteria

• Cervical stenosis

• Recurrent pregnancy loss defined by recurrent non-biochemical pregnancy losses

• Failed fertilization of all oocytes obtained in a previous IVF cycle

• Smoke tobacco or vape, abuse drugs or alcohol

• Inability to understand or comply with trial procedures

• Partner with vasectomy reversal

• Partner with inability to produce sperm specimen

• Partner with uro-genital infection

Related Conditions & MeSH terms

• Infertility

Intervention

Device:
• INVOcell
Female participants undergoing in vitro fertilization (IVF) and/or Intracytoplasmic Sperm Injection (ICSI) for assisted reproduction will be asked to participate.

Locations

Country	Name	City	State
United States	Piedmont Reproductive Endocrinology Group	Greenville	South Carolina
United States	Fertility Center of San Antonio	San Antonio	Texas
United States	The New Hope Center for Reproductive Medicine	Virginia Beach	Virginia
United States	Piedmont Reproductive Endocrinology Group	West Columbia	South Carolina

Sponsors (2)

Lead Sponsor	Collaborator
INVO Bioscience, Inc.	Ferring Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical Pregnancy Rate	Clinical pregnancy rate: number of clinical pregnancies at 7 weeks of gestation divided by the number of successful egg retrieval procedures.	at 7 weeks of gestation